Keyword: Fujifilm Diosynth Biotechnologies
Fujifilm will buy biologics operations in Denmark from Biogen as the Japanese company continues to beef up its CDMO business.
Fujifilm to expand its production facility in North Carolina to support increased customer needs.
Drug materials are targets of U.S.-China trade war, analysts see more hope in the Takeda-Shire deal, China puts forward policies that favors generics over brands.
Fujifilm continues to expand its healthcare footprint with the recent acquisition of a pair of cell culture media units for about $800 million.
Japan’s Fujifilm will build a plant to produce liposomes that can be the delivery vehicles for some new drug candidates.
WuXi NextCODE has raised $240 million in series B, FDA slapped Celltrion with a long Form 483, Biocon's $275 million insulin plant opened shop.
Japan's Fujifilm Diosynth Biotechnologies has completed a $9 million expansion project of its cell manufacturing facilities in the U.K.
Takeda is relocating hundreds of jobs, a key Velcade patent was restored till 2022, 36 drugs were added to China's insurance drug list after huge discounts.
AGC Asahi Glass, which bought CMC Biologics this year, will make its Seattle, Washington, area operation the headquarters of its drug business.
Novartis' CEO said China's pharma market will surpass $300 billion by 2020, Hanmi failed to report olmutinib side effect on time, Celgene tapped first Asia-Pacific partner.